{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:02:01Z","timestamp":1769626921228,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bayer Healthcare Company Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12325-022-02389-7","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T08:02:47Z","timestamp":1673424167000},"page":"1087-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost\u2013Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-6391","authenticated-orcid":false,"given":"Jian","family":"Ming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reg","family":"Waldeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanlian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"2389_CR1","unstructured":"WHO. Estimated crude incidence\/mortality rates in 2020 prostate, males, all ages. Global Cancer Observatory website. Retrieved 2021, from https:\/\/gco.iarc.fr\/today\/home."},{"key":"2389_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.853623","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Wang C, Xia H, et al. Burden of prostate cancer in China, 1990\u20132019: findings from the 2019 global burden of disease study. Front Endocrinol (Lausanne). 2022;13: 853623. https:\/\/doi.org\/10.3389\/fendo.2022.853623.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2389_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","volume":"70","author":"MC Wong","year":"2016","unstructured":"Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862\u201374. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.043.","journal-title":"Eur Urol"},{"issue":"6","key":"2389_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/iju.13593","volume":"25","author":"T Kimura","year":"2018","unstructured":"Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524\u201331. https:\/\/doi.org\/10.1111\/iju.13593.","journal-title":"Int J Urol"},{"issue":"6","key":"2389_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3760\/cma.j.issn.0253-9624.2018.06.006","volume":"52","author":"XY Gu","year":"2018","unstructured":"Gu XY, Zhang RS, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014. Chin J Prev Med. 2018;52(6):586\u201392. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-9624.2018.06.006.","journal-title":"Chin J Prev Med"},{"issue":"10","key":"2389_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139440","volume":"10","author":"HI Scher","year":"2015","unstructured":"Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS\u00a0One. 2015;10(10): e0139440. https:\/\/doi.org\/10.1371\/journal.pone.0139440.","journal-title":"PLoS\u00a0One"},{"issue":"13","key":"2389_CR7","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23(13):2918\u201325. https:\/\/doi.org\/10.1200\/JCO.2005.01.529.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2389_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M N\u00f8rgaard","year":"2010","unstructured":"N\u00f8rgaard M, Jensen A, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162\u20137. https:\/\/doi.org\/10.1016\/j.juro.2010.03.034.","journal-title":"J Urol"},{"issue":"3","key":"2389_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2015-0327","volume":"21","author":"JA McDougall","year":"2016","unstructured":"McDougall JA, Bansal A, Goulart BH, et al. The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone. Oncologist. 2016;21(3):320\u20136. https:\/\/doi.org\/10.1634\/theoncologist.2015-0327.","journal-title":"Oncologist"},{"issue":"5b","key":"2389_CR10","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1111\/bju.13856","volume":"120","author":"LE Howard","year":"2017","unstructured":"Howard LE, Moreira DM, De Hoedt A, et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017;120(5b):e80-e86. https:\/\/doi.org\/10.1111\/bju.13856.","journal-title":"BJU Int"},{"issue":"7","key":"2389_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","volume":"18","author":"SD Lokeshwar","year":"2021","unstructured":"Lokeshwar SD, Klaassen Z, Saad F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat Rev Urol. 2021;18(7):433\u201342. https:\/\/doi.org\/10.1038\/s41585-021-00470-4.","journal-title":"Nat Rev Urol"},{"key":"2389_CR12","unstructured":"Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of prostate cancer (2021 edition). 2021."},{"key":"2389_CR13","unstructured":"Liu G, Hu S, Wu J, et al. China guidelines for pharmacoeconomic evaluations (2020 edition). 2020."},{"key":"2389_CR14","unstructured":"National Bureau of Statistics. Statistic report on national economic and social development in 2021. Retrieved from http:\/\/www.stats.gov.cn\/tjsj\/zxfb\/202202\/t20220227_1827960.html."},{"key":"2389_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"10","key":"2389_CR16","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345. https:\/\/doi.org\/10.2165\/11538370-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"2389_CR17","unstructured":"National Bureau of Statistics. China population and employment statistics yearbook 2017."},{"issue":"23","key":"2389_CR18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2003892.","journal-title":"N Engl J Med"},{"issue":"1","key":"2389_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79(1):150\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011.","journal-title":"Eur Urol"},{"issue":"11","key":"2389_CR20","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2001342.","journal-title":"N Engl J Med"},{"issue":"1","key":"2389_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5582\/bst.2017.01244","volume":"12","author":"F Li","year":"2018","unstructured":"Li F, Zhu B, He Z, et al. Exploring the determinants that influence end-of-life hospital costs of the elderly in Shanghai, China. Biosci Trends. 2018;12(1):87\u201393. https:\/\/doi.org\/10.5582\/bst.2017.01244.","journal-title":"Biosci Trends"},{"issue":"8","key":"2389_CR22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40273-020-00915-5","volume":"38","author":"M Paulden","year":"2020","unstructured":"Paulden M. Why it\u2019s time to abandon the ICER. Pharmacoeconomics. 2020;38(8):781\u20134. https:\/\/doi.org\/10.1007\/s40273-020-00915-5.","journal-title":"Pharmacoeconomics"},{"key":"2389_CR23","unstructured":"National Institute for Health and Care Excellence. TA387: abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. 2016. Retrieved from https:\/\/www.nice.org.uk\/guidance\/ta387."},{"key":"2389_CR24","unstructured":"National Institute for Health and Care Excellence. TA377: enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. 2015. Retrieved from https:\/\/www.nice.org.uk\/guidance\/ta377."},{"issue":"1","key":"2389_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41391-020-00271-7","volume":"24","author":"RR McKay","year":"2021","unstructured":"McKay RR, Silver R, Bhak RH, et al. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer Prostatic Dis. 2021;24(1):210\u20139. https:\/\/doi.org\/10.1038\/s41391-020-00271-7.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"2389_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1185\/03007991003712258","volume":"26","author":"P Swinburn","year":"2010","unstructured":"Swinburn P, Lloyd A, Nathan P, et al. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin. 2010;26(5):1091\u20136. https:\/\/doi.org\/10.1185\/03007991003712258.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2389_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.lungcan.2008.03.019","volume":"62","author":"S Doyle","year":"2008","unstructured":"Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer. 2008;62(3):374\u201380. https:\/\/doi.org\/10.1016\/j.lungcan.2008.03.019.","journal-title":"Lung Cancer"},{"issue":"6","key":"2389_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683\u201390. https:\/\/doi.org\/10.1038\/sj.bjc.6603326.","journal-title":"Br J Cancer"},{"key":"2389_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84. https:\/\/doi.org\/10.1186\/1477-7525-6-84.","journal-title":"Health Qual Life Outcomes"},{"key":"2389_CR30","unstructured":"National Institute for Health and Care Excellence. TA660: darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer. Technology appraisal guidance. 2020. Retrieved from https:\/\/www.nice.org.uk\/guidance\/ta660."},{"key":"2389_CR31","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology prostate cancer version 1. 2021."},{"key":"2389_CR32","unstructured":"National Healthcare Security Administration. Interim measures for the administration of use of drugs covered by the basic medical insurance. 2020. Retrieved from http:\/\/www.nhsa.gov.cn\/art\/2020\/7\/31\/art_104_6492.html."},{"issue":"5","key":"2389_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.clgc.2020.02.005","volume":"18","author":"AE Hird","year":"2020","unstructured":"Hird AE, Magee DE, Bhindi B, et al. A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2020;18(5):343\u201350. https:\/\/doi.org\/10.1016\/j.clgc.2020.02.005.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"2389_CR34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.urolonc.2020.03.022","volume":"38","author":"J Kumar","year":"2020","unstructured":"Kumar J, Jazayeri SB, Gautam S, et al. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis. Urol Oncol. 2020;38(11):826\u201334. https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.022.","journal-title":"Urol Oncol"},{"issue":"11","key":"2389_CR35","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","volume":"25","author":"K Mori","year":"2020","unstructured":"Mori K, Mostafaei H, Pradere B, et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020;25(11):1892\u2013900. https:\/\/doi.org\/10.1007\/s10147-020-01777-9.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"2389_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/coc.0000000000000660","volume":"43","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhang T, Ma Z, et al. Systemic management for nonmetastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Am J Clin Oncol. 2020;43(4):288\u201397. https:\/\/doi.org\/10.1097\/coc.0000000000000660.","journal-title":"Am J Clin Oncol"},{"issue":"6_suppl","key":"2389_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1200\/JCO.2020.38.6_suppl.113","volume":"38","author":"E Cusano","year":"2020","unstructured":"Cusano E, Lee-Ying RM, Boyne DJ, et al. Systemic therapy for nonmetastatic castrate-resistant prostate cancer (M0 CRPC): a systematic review and network meta-analysis (NMA). J Clin Oncol. 2020;38(6_suppl):113\u2013113. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.113.","journal-title":"J Clin Oncol"},{"key":"2389_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00395-4","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, Nocera L, Coll\u00e0 Ruvolo C, et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. 2021. https:\/\/doi.org\/10.1038\/s41391-021-00395-4.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2389_CR39","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"AM Moilanen","year":"2015","unstructured":"Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007. https:\/\/doi.org\/10.1038\/srep12007.","journal-title":"Sci Rep"},{"issue":"6_suppl","key":"2389_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1200\/JCO.2018.36.6_suppl.345","volume":"36","author":"C Zurth","year":"2018","unstructured":"Zurth C, Sandmann S, Trummel D, et al. Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography. J Clin Oncol. 2018;36(6_suppl):345\u2013345. https:\/\/doi.org\/10.1200\/JCO.2018.36.6_suppl.345.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2389_CR41","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1200\/JCO.2020.38.15_suppl.5583","volume":"38","author":"IB Riaz","year":"2020","unstructured":"Riaz IB, Almutairi A, Lang DK, et al. Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;38(15_suppl):5583\u20135583. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5583.","journal-title":"J Clin Oncol"},{"key":"2389_CR42","doi-asserted-by":"publisher","first-page":"S478","DOI":"10.1016\/j.jval.2019.09.414","volume":"22","author":"M Tsiatas","year":"2019","unstructured":"Tsiatas M, van Oostrum I, Tritaki G, et al. PCN218 cost-effectiveness of apalutamide + ADT versus enzalutamide + ADT in non-metastatic castration resistant prostate cancer in Greece. Value Health. 2019;22:S478. https:\/\/doi.org\/10.1016\/j.jval.2019.09.414.","journal-title":"Value Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02389-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:26:45Z","timestamp":1678087605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02389-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2389"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02389-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}